(Q38212259)

31 August 2017

title

The current role of mitoxantrone in the treatment of multiple sclerosis (English)

1 reference

31 August 2017

0 references

Eleonora Cocco

1

0 references

Maria Giovanna Marrosu

object named as

Maria Giovanna Marrosu

series ordinal

2

0 references

publication date

16 May 2014

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

31 August 2017

published in

1 reference

31 August 2017

volume

14

1 reference

31 August 2017

issue

6

1 reference

31 August 2017

page(s)

607-616

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

31 August 2017

1 reference

The worldwide prevalence of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Temporal trends in the incidence of multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Incidence and prevalence of multiple sclerosis in Europe: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Managing MS in a changing treatment landscape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Concepts of induction and escalation therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Induction therapy for patients with multiple sclerosis: why? When? How?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Mitoxantrone and cytotoxic drugs' mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Suppression of experimental allergic encephalomyelitis by mitoxantrone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

The relevance of animal models in multiple sclerosis research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Suppression of demyelination by mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Treatment of multiple sclerosis with mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

An open-trial evaluation of mitoxantrone in the treatment of progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Assessment of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis: a tissue Doppler echocardiographic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab's withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

The Will Rogers phenomenon: the effect of different diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2014.915742

10.1586/14737175.2014.915742

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference